Literature DB >> 8347133

Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Immunoassay of human aldose reductase.

C Nishimura1, M Furue, T Ito, Y Omori, T Tanimoto.   

Abstract

An antibody-sandwich enzyme-linked immunosorbent assay (ELISA) for evaluating tissue levels of aldose reductase was developed using a polyclonal antibody prepared against the recombinant enzyme expressed in a baculovirus system. The specificity of this antibody to aldose reductase was verified by immunoprecipitation, immunoblotting and ELISA. The polyclonal antibody did not crossreact with human aldehyde reductase, an enzyme in the same aldo-keto reductase family structurally and functionally related to aldose reductase. The sensitivity and specificity of this assay method enabled direct determination of aldose reductase level in various human tissues including the erythrocyte. The highest level of aldose reductase was detected in the kidney medulla among tissues investigated. More than a 2-fold variability in the erythrocyte aldose reductase was demonstrated among healthy individuals, indicating the heterogeneity of this enzyme expression in a human population. This assay system may be useful for direct measurement of the level of tissue aldose reductase in conjunction with the evaluation of the efficacy of aldose reductase inhibitors prescribed for the treatment of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347133     DOI: 10.1016/0006-2952(93)90343-u

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?

Authors:  Kenneth H Gabbay
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

2.  Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.

Authors:  Daniel P K Ng; Charles L Hardy; Wendy C Burns; Evelyne E Muggli; Nicole Kerr; Jane McCausland; Daine Alcorn; Timothy E Adams; Jeffrey D Zajac; Richard G Larkins; Marjorie E Dunlop
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

3.  Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA.

Authors:  T Yamaoka; C Nishimura; K Yamashita; M Itakura; T Yamada; J Fujimoto; Y Kokai
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

4.  High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.

Authors:  C Nishimura; T Saito; T Ito; Y Omori; T Tanimoto
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

Review 5.  Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.

Authors:  Naila Rabbani; Mingzhan Xue; Paul J Thornalley
Journal:  Glycoconj J       Date:  2016-07-12       Impact factor: 2.916

6.  Hormetic potential of methylglyoxal, a side-product of glycolysis, in switching tumours from growth to death.

Authors:  Marie-Julie Nokin; Florence Durieux; Justine Bellier; Olivier Peulen; Koji Uchida; David A Spiegel; James R Cochrane; Craig A Hutton; Vincent Castronovo; Akeila Bellahcène
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

Review 7.  Role of the Glyoxalase System in Breast Cancer and Gynecological Cancer-Implications for Therapeutic Intervention: a Review.

Authors:  Jingyuan Wang; Xiao Yang; Zhiqi Wang; Jianliu Wang
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.